Koru Medical Systems Inc (KRMD) Stock Price, Quote & News

Company Profile

KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH)....

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 845 469 2042

Fax: 845 469 5518

Website: www.korumedical.com

Address:

100 Corporate Drive, Mahwah, United States

pufferfishcapital May. 8 at 12:42 AM

$KRMD solid execution shown Q1 w new CEO likely to accelerate push into non IG. Underappreciated IMO how large the opportunity is in infusion centers, especially oncology drugs, which can be maddening for nurses to push manually multiple patients. Valuation very modest

0 · Reply

StocktwitsEarnings May. 6 at 8:14 PM

$KRMD Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.02 up 33.33% YoY • Reported revenue of $11.76M up 22.10% YoY • Koru Medical Systems amended its loan agreement, extending the $5,000,000 revolver maturity to March 30, 2028, and the $5,000,000 term loan maturity to December 1, 2029, while lowering the interest rate floor to 5.50%.

0 · Reply

GoGreen21 May. 6 at 1:52 PM

$KRMD https://www.marketbeat.com/instant-alerts/koru-medical-systems-krmd-to-release-earnings-on-wednesday-2026-04-29/

0 · Reply

GoGreen21 May. 6 at 1:46 PM

$KRMD Earnings after hours today. Why dont they announce it on here??

0 · Reply

BillionerOfKing May. 1 at 3:51 AM

$KRMD Current Stock Price: $3.97 Contracts to trade: $5.0 KRMD May 15 2026 Call Entry: $0.41 Exit: $0.80 ROI: 99% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

theDIOyears Apr. 24 at 3:20 AM

$KRMD they mentioned some exposure in the Middle East now. How much exposure are we talking about? Going to do some digging into this. Anybody have any thoughts??

0 · Reply

SuperGreenToday Apr. 6 at 3:43 PM

$KRMD Share Price: $4.34 Contract Selected: Nov 20, 2026 $5 Calls Buy Zone: $0.23 – $0.28 Target Zone: $0.39 – $0.48 Potential Upside: 60% ROI Time to Expiration: 227 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

OfficialStocktwitsUser Apr. 3 at 1:39 AM

$KRMD RSI: 52.22, MACD: -0.1299 Vol: 0.11, MA20: 4.36, MA50: 4.75 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

GoGreen21 Mar. 13 at 12:25 AM

$KRMD Loaded a few after hours.

1 · Reply

StocktwitsEarnings Mar. 12 at 8:18 PM

$KRMD Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.01 up 66.67% YoY • Reported revenue of $10.9M up 23.27% YoY

0 · Reply

KORU Medical Systems Earnings Call Transcript: Q1 2026

May 6, 2026, 4:05 PM EDT - 1 day ago

KORU Medical Systems Announces First Quarter 2026 Results

Apr 16, 2026, 8:00 AM EDT - 21 days ago

KORU Medical Systems to Report First Quarter 2026 Financial Results on May 6, 2026

Mar 13, 2026, 8:00 AM EDT - 7 weeks ago

KORU Medical Systems Announces EU MDR Certification for the Freedom60® Infusion Pump With Prefilled Syringe Compatibility

Mar 12, 2026, 4:30 PM EDT - 2 months ago

KORU Medical Systems Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:08 PM EDT - 2 months ago

KORU Medical Systems Announces CEO Transition

Mar 12, 2026, 4:05 PM EDT - 2 months ago

KORU Medical Systems Announces +20% Fourth Quarter and Full Year 2025 Revenue Growth, Positive Adjusted EBITDA and Initiates Full Year 2026 Guidance

Feb 26, 2026, 4:05 PM EST - 2 months ago

KORU Medical Systems to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Jan 29, 2026, 4:05 PM EST - 3 months ago

KORU Medical Systems Receives FDA 510(k) Clearance for Delivery of RYSTIGGO® (rozanolixizumab-noli), Expanding Label for FreedomEDGE® Infusion System

Jan 12, 2026, 8:00 AM EST - 4 months ago

KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow

Jan 5, 2026, 7:00 AM EST - 4 months ago

KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 30, 2025, 4:05 PM EST - 4 months ago

KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE® System with a Commercialized Oncology Biologic

Dec 16, 2025, 4:05 PM EST - 5 months ago

KORU Medical Systems, Inc. Appoints Eric Schiller as Chief Technology Officer

Dec 2, 2025, 9:30 AM EST - 5 months ago

KORU Medical Systems Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 4:05 PM EST - 6 months ago

KORU Medical Systems to Present Promising Results on the Use of the FreedomEDGE® Syringe Infusion System in Infusion Centers at ESID/EHA/SIOPE Focused Symposium 2025

Nov 13, 2025, 8:00 AM EST - 6 months ago

KORU Medical Systems to Participate in Upcoming Investor Conferences

Nov 12, 2025, 4:30 PM EST - 6 months ago

KORU Medical Systems Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:05 PM EST - 6 months ago

KORU Medical Systems Announces 27% Q3 Revenue Growth and Raises 2025 Revenue Guidance

Nov 4, 2025, 4:05 PM EST - 6 months ago

KORU Medical Systems Announces Development Agreement for Innovation in Subcutaneous Immunoglobulin Infusion Systems

Oct 22, 2025, 4:05 PM EDT - 7 months ago

KORU Medical Systems to Report Third Quarter 2025 Financial Results on November 12, 2025

Sep 18, 2025, 8:00 AM EDT - 8 months ago

ForCast Orthopedics and KORU Medical Systems Announce Agreement for Novel Antibiotic Infusion Therapy

Aug 28, 2025, 12:59 PM EDT - 9 months ago

Cirtec Medical Announces Appointment of New Chief Executive Officer

Aug 13, 2025, 10:30 AM EDT - 9 months ago

KORU Medical Systems Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 6, 2025, 4:30 PM EDT - 9 months ago

KORU Medical Systems Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:05 PM EDT - 9 months ago

KORU Medical Systems Announces Q2 2025 Financial Results, Including Record Double-digit Revenue, and Raises 2025 Revenue Guidance

Jul 30, 2025, 4:05 PM EDT - 10 months ago

KORU Medical Systems to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 16, 2025, 4:05 PM EDT - 10 months ago

KORU Medical Systems to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 7, 2025, 4:05 PM EDT - 10 months ago

KORU Medical Systems Appoints Adam Kalbermatten as Chief Commercial Officer

Jun 11, 2025, 4:05 PM EDT - 11 months ago

KORU Medical Systems to Join Russell 3000® and Russell 2000® Indexes

May 7, 2025, 4:30 PM EDT - 1 year ago

KORU Medical Systems Earnings Call Transcript: Q1 2025

May 7, 2025, 4:05 PM EDT - 1 year ago

KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance

Mar 12, 2025, 4:30 PM EDT - 1 year ago

KORU Medical Systems Earnings Call Transcript: Q4 2024

Mar 12, 2025, 4:05 PM EDT - 1 year ago

KORU Medical Systems Announces Fourth Quarter and Full Year 2024 Financial Results With Record Revenues and Gross Profit; Issues Full Year 2025 Guidance

Feb 19, 2025, 4:05 PM EST - 1 year ago

KORU Medical Systems to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

Feb 6, 2025, 4:05 PM EST - 1 year ago

KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System

Jan 30, 2025, 4:05 PM EST - 1 year ago

KORU Medical Systems Announces Phase III Clinical Trial Collaboration for a New Drug Indication in Nephrology

Jan 13, 2025, 8:00 AM EST - 1 year ago

KORU Medical Systems Reports Preliminary Fourth Quarter and Full Year 2024 Results; Achieves Record Full Year and Quarterly Revenues; Positive Cash Flow for the Fourth Quarter

Dec 5, 2024, 11:00 AM EST - 1 year ago

KORU Medical Systems Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 4:05 PM EST - 1 year ago

KORU Medical Systems to Participate in Piper Sandler's 36th Annual Healthcare Conference

Nov 13, 2024, 4:30 PM EST - 1 year ago

KORU Medical Systems Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:05 PM EST - 1 year ago

KORU Medical Systems, Inc. Announces 2024 Q3 Financial Results, Third Consecutive Quarter of Double-Digit Growth; Raises Full Year 2024 Guidance

Oct 31, 2024, 4:03 PM EDT - 1 year ago

KORU Medical Systems Presents Data at Partnership Opportunities in Drug Delivery (PODD) Conference Demonstrating Nursing Preference for Use of KORU FreedomEdge® Infusion System over Manual Syringe Administration for Subcutaneous Oncology Infusion

Oct 23, 2024, 4:05 PM EDT - 1 year ago

KORU Medical Systems to Report Third Quarter 2024 Financial Results on November 13, 2024

Sep 5, 2024, 7:00 AM EDT - 1 year ago

KORU Medical Systems to Participate in the 8th Annual Lake Street Best Ideas Growth Conference

Aug 14, 2024, 8:30 AM EDT - 1 year ago

KORU Medical Systems Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

Aug 7, 2024, 4:30 PM EDT - 1 year ago

KORU Medical Systems Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

KORU Medical Systems, Inc. Announces 2024 Q2 Financial Results, a Record Quarter With 22% Revenue Growth; Raises Full Year 2024 Guidance

Jul 25, 2024, 4:05 PM EDT - 1 year ago

KORU Medical Systems to Participate in the Canaccord Genuity 44th Annual Growth Conference

Jul 24, 2024, 4:05 PM EDT - 1 year ago

KORU Medical Systems, Inc Announces Leadership Changes to Support Growth Agenda

Jul 17, 2024, 4:05 PM EDT - 1 year ago

KORU Medical Systems to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 2, 2024, 7:00 AM EDT - 2 years ago

KORU Medical Systems Receives Regulatory Clearance for FreedomEdge® Infusion System in Japan

Jun 5, 2024, 9:00 AM EDT - 2 years ago

Simplifying Subcutaneous Drug Administration: SCHOTT Pharma and KORU Medical Systems Announce Collaboration to Advance Large Volume Subcutaneous Infusion

Jun 4, 2024, 4:03 PM EDT - 2 years ago

KORU Medical Systems Announces a New Feasibility Study with a Commercialized Oncology Biologic

May 14, 2024, 4:05 PM EDT - 2 years ago

KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic

May 1, 2024, 4:30 PM EDT - 2 years ago

KORU Medical Systems Earnings Call Transcript: Q1 2024

May 1, 2024, 4:05 PM EDT - 2 years ago

KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth

Apr 17, 2024, 7:00 AM EDT - 2 years ago

KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024

Apr 11, 2024, 4:05 PM EDT - 2 years ago

KORU Medical Systems Announces Successful Appeal in EU Notified Body Review

Mar 18, 2024, 5:24 PM EDT - 2 years ago

KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference

Mar 13, 2024, 4:30 PM EDT - 2 years ago

KORU Medical Systems Earnings Call Transcript: Q4 2023

Mar 13, 2024, 4:05 PM EDT - 2 years ago

KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance

Mar 11, 2024, 4:05 PM EDT - 2 years ago

KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic

Mar 6, 2024, 7:00 AM EST - 2 years ago

KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin

Feb 21, 2024, 7:00 AM EST - 2 years ago

KORU Medical Systems to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

pufferfishcapital May. 8 at 12:42 AM

0 · Reply

StocktwitsEarnings May. 6 at 8:14 PM

0 · Reply

GoGreen21 May. 6 at 1:52 PM

$KRMD https://www.marketbeat.com/instant-alerts/koru-medical-systems-krmd-to-release-earnings-on-wednesday-2026-04-29/

0 · Reply

GoGreen21 May. 6 at 1:46 PM

$KRMD Earnings after hours today. Why dont they announce it on here??

0 · Reply

BillionerOfKing May. 1 at 3:51 AM

0 · Reply

theDIOyears Apr. 24 at 3:20 AM

$KRMD they mentioned some exposure in the Middle East now. How much exposure are we talking about? Going to do some digging into this. Anybody have any thoughts??

0 · Reply

SuperGreenToday Apr. 6 at 3:43 PM

0 · Reply

OfficialStocktwitsUser Apr. 3 at 1:39 AM

0 · Reply

GoGreen21 Mar. 13 at 12:25 AM

$KRMD Loaded a few after hours.

1 · Reply

StocktwitsEarnings Mar. 12 at 8:18 PM

$KRMD Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.01 up 66.67% YoY • Reported revenue of $10.9M up 23.27% YoY

0 · Reply

OfficialStocktwitsUser Feb. 26 at 7:21 PM

$KRMD RSI: 53.97, MACD: -0.1700 Vol: 0.35, MA20: 4.91, MA50: 5.43 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

NVDAMillionaire Feb. 4 at 4:04 PM

$KRMD Outstanding article that hits the mark on KRMD's current state. So if you want to refresh your KRMD insights or learn about KRMD from scratch, this is a must read. https://everyticker.com/quote/KRMD/analysis/koru-medical-systems-nasdaq-krmd-unlocking-growth-through-subcutaneous-innovation-and-global-expansion

0 · Reply

OfficialStocktwitsUser Feb. 2 at 5:59 PM

$KRMD RSI: 39.01, MACD: -0.0313 Vol: 0.12, MA20: 5.62, MA50: 5.65 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

copywrites Jan. 29 at 9:22 PM

$KRMD really good news! congratulations 🎉

0 · Reply

Gesundheit Jan. 20 at 7:48 AM

$KRMD I have been with KRMD since 2020. Very predictable. There will be down pressure for a while since next earnings is not till March even though they have already spilled the beans that it will be good. Funds are wanting in but at a better price. Anything in the $5.00 range should work well if you are looking to hold long.

0 · Reply

Paper_Route_Frank Jan. 17 at 1:15 PM

$KRMD avg 5.73 light position

0 · Reply

OfficialStocktwitsUser Jan. 7 at 12:47 AM

$KRMD RSI: 45.63, MACD: 0.1493 Vol: 0.28, MA20: 5.86, MA50: 5.08 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ZacksResearch Dec. 31 at 6:17 PM

Big move for $KRMD — oncology expansion just got real. ⚠️💡 KORU Medical filed a 510(k) to use the FreedomEDGE System for subcutaneous PHESGO delivery, expanding into oncology while aiming to simplify breast cancer care. See why this regulatory step matters 👉 https://www.zacks.com/stock/news/2810902/krmd-submits-510k-to-use-freedomedge-system-with-oncology-biologic?cid=sm-stocktwits-2-2810902-teaser-27048&ADID=SYND_STOCKTWITS_TWEET_2_2810902_TEASER_27048

0 · Reply

ZacksResearch Dec. 31 at 5:17 PM

$KRMD saw a 6.1% decline following the announcement of a major FDA filing! 📉 KORU Medical submits a 510(k) for its FreedomEDGE system to deliver PHESGO subcutaneously, aiming to simplify cancer treatment and expand its market in oncology. Understand the strategic impact here 👉 https://www.zacks.com/stock/news/2810902/krmd-submits-510k-to-use-freedomedge-system-with-oncology-biologic?cid=sm-stocktwits-2-2810902-body-27038&ADID=SYND_STOCKTWITS_TWEET_2_2810902_BODY_27038

0 · Reply

copywrites Dec. 31 at 6:22 AM

$KRMD PHESGO here we come, Roche Drug onboarding ✅

0 · Reply

Gesundheit Dec. 30 at 3:15 PM

$KRMD Another dip, buy point coming up. :)

0 · Reply

ThesisTrader Dec. 25 at 9:44 AM

$KRMD Forward momentum is increasingly dictated by operational clarity, amid evolving funding conditions and shifting competitive responses. Clear follow‑through could unlock sustainable re‑rating.

0 · Reply

Market Cap	186.91M
Revenue (ttm)	41.13M
Net Income (ttm)	-2.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6.42%
Debt to Equity Ratio	0.00

Volume	380,700
Avg Vol	144,962
Day's Range	N/A - N/A
Shares Out	46.61M
Stochastic %K	68%
Beta	0.43
Analysts	Strong Sell
Price Target	$6.80